Loading...
•
Jun 30, 2020
Bicycle Q2 2020 Earnings Report
Reported financial results for the second quarter ended June 30, 2020.
Key Takeaways
Bicycle Therapeutics reported their financial results for the second quarter of 2020, highlighting progress towards their 2020 objectives despite challenges from the COVID-19 pandemic. They are advancing clinical trials for BT1718, BT8009 and BT5528.
Initiating Phase IIa trial of BT1718.
Initiating Phase I/II trial of BT8009.
Advancing BT5528 in the dose escalation portion of a Phase I/II trial.
Deploying proprietary EphA2 immunohistochemistry assay to select and enroll EphA2-positive patients in the Phase I trial.
Forward Guidance
Bicycle Therapeutics is focused on advancing clinical trials and achieving near-term milestones to develop novel therapies for cancer and other serious diseases.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...